论文部分内容阅读
70年代,血管扩张剂的临床应用开创了处理慢性充血性心力衰竭(以下简称心力衰竭)的新领域。随着血管扩张剂的广泛应用,更要求明确心力衰竭周围循环中各个部位的血管张力改变的发生机制。其中肾素-血管紧张素-醛固酮系统(以下称RAA系统)在心力衰竭病理生理学中的地位再次被受到重视。巯甲丙脯酸(captopril,以下称CPT)是一种血管紧张素转换酶抑制剂,70年代早期首先应用于高血压病的治疗,近5年来已应用于治疗心力衰竭。不但临床疗效满意,而且对进一步了解RAA系统在心力衰竭发生中的地位也具有十分重要的意义。
In the seventies, the clinical application of vasodilators opened up new areas for the treatment of chronic congestive heart failure (hereinafter referred to as heart failure). With the wide application of vasodilators, it is even required to clarify the mechanism of vascular tension changes in various parts of the circulation around the heart failure. Among them, the renin-angiotensin-aldosterone system (hereinafter referred to as RAA system) plays a more important role in the pathophysiology of heart failure. Captopril (hereinafter referred to as CPT) is an angiotensin converting enzyme inhibitor. It was first applied to the treatment of hypertension in the early 1970s and has been used to treat heart failure in the past five years. Not only the clinical efficacy is satisfactory, but also has a very important significance for further understanding of the status of RAA system in the occurrence of heart failure.